AAAAAA

   
Results: 1-12 |
Results: 12
Convergent synthesis of potent peptide inhibitors of the Grb2-SH2 domain by palladium catalyzed coupling of a terminal alkyne
Authors: Schoepfer, J Gay, B End, N Muller, E Scheffel, G Caravatti, G Furet, P
Citation: J. Schoepfer et al., Convergent synthesis of potent peptide inhibitors of the Grb2-SH2 domain by palladium catalyzed coupling of a terminal alkyne, BIOORG MED, 11(9), 2001, pp. 1201-1203
Synthesis of (+)-(R)-methyl 2-aminotetraline-2-carboxylate: the hydroxypinanone method versus the bislactim method
Authors: Solladie-Cavallo, A Martin-Cabrejas, LM Caravatti, G Lang, M
Citation: A. Solladie-cavallo et al., Synthesis of (+)-(R)-methyl 2-aminotetraline-2-carboxylate: the hydroxypinanone method versus the bislactim method, TETRAHEDR-A, 12(7), 2001, pp. 967-969
Tyrosine kinase inhibitors: From rational design to clinical trials
Authors: Traxler, P Bold, G Buchdunger, E Caravatti, G Furet, P Manley, P O'Reilly, T Wood, J Zimmermann, J
Citation: P. Traxler et al., Tyrosine kinase inhibitors: From rational design to clinical trials, MED RES REV, 21(6), 2001, pp. 499-512
Synthesis and biological evaluation of highly potent analogues of epothilones B and D
Authors: Altmann, KH Bold, G Caravatti, G Florsheimer, A Guagnano, V Wartmann, M
Citation: Kh. Altmann et al., Synthesis and biological evaluation of highly potent analogues of epothilones B and D, BIOORG MED, 10(24), 2000, pp. 2765-2768
Structure-based design and synthesis of phosphinate isosteres of phosphotyrosine for incorporation in Grb2-SH2 domain inhibitors. Part 1
Authors: Furet, P Caravatti, G Denholm, AA Faessler, A Fretz, H Garcia-Echeverria, C Gay, B Irving, E Press, NJ Rahuel, J Schoepfer, J Walker, CV
Citation: P. Furet et al., Structure-based design and synthesis of phosphinate isosteres of phosphotyrosine for incorporation in Grb2-SH2 domain inhibitors. Part 1, BIOORG MED, 10(20), 2000, pp. 2337-2341
Structure-based design and synthesis of phosphinate isosteres of phosphotyrosine for incorporation in Grb2-SH2 domain inhibitors. Part 2
Authors: Walker, CV Caravatti, G Denholm, AA Egerton, J Faessler, A Furet, P Garcia-Echeverria, C Gay, B Irving, E Jones, K Lambert, A Press, NJ Woods, J
Citation: Cv. Walker et al., Structure-based design and synthesis of phosphinate isosteres of phosphotyrosine for incorporation in Grb2-SH2 domain inhibitors. Part 2, BIOORG MED, 10(20), 2000, pp. 2343-2346
Epothilones and their analogs - Potential new weapons in the fight againstcancer
Authors: Altmann, KH Bold, G Caravatti, G End, N Florsheimer, A Guagnano, V O'Reilly, T Wartmann, M
Citation: Kh. Altmann et al., Epothilones and their analogs - Potential new weapons in the fight againstcancer, CHIMIA, 54(11), 2000, pp. 612-621
Highly potent inhibitors of the Grb2-SH2 domain
Authors: Schoepfer, J Fretz, H Gay, B Furet, P Garcia-Echeverria, C End, N Caravatti, G
Citation: J. Schoepfer et al., Highly potent inhibitors of the Grb2-SH2 domain, BIOORG MED, 9(2), 1999, pp. 221-226
Structure-based design of a non-peptidic antagonist of the SH2 domain of Grb2
Authors: Caravatti, G Rahuel, J Gay, B Furet, P
Citation: G. Caravatti et al., Structure-based design of a non-peptidic antagonist of the SH2 domain of Grb2, BIOORG MED, 9(14), 1999, pp. 1973-1978
Effect of potent and selective inhibitors of the Grb2 SH2 domain on cell motility
Authors: Gay, B Suarez, S Weber, C Rahuel, J Fabbro, D Furet, P Caravatti, G Schoepfer, J
Citation: B. Gay et al., Effect of potent and selective inhibitors of the Grb2 SH2 domain on cell motility, J BIOL CHEM, 274(33), 1999, pp. 23311-23315
Selective GRB2 SH2 inhibitors as anti-Ras therapy
Authors: Gay, B Suarez, S Caravatti, G Furet, P Meyer, T Schoepfer, J
Citation: B. Gay et al., Selective GRB2 SH2 inhibitors as anti-Ras therapy, INT J CANC, 83(2), 1999, pp. 235-241
A derivative of staurosporine (CGP 41 : 251) shows selectivity for PKC inhibition and in vitro antiproliferative effects as well as in vivo antitumoractivity. (vol 43, pg 851, 1989)
Authors: Meyer, T Regenass, U Fabbro, D Alteri, E Rosel, J Muller, M Caravatti, G Matter, A
Citation: T. Meyer et al., A derivative of staurosporine (CGP 41 : 251) shows selectivity for PKC inhibition and in vitro antiproliferative effects as well as in vivo antitumoractivity. (vol 43, pg 851, 1989), INT J CANC, 81(4), 1999, pp. 669-669
Risultati: 1-12 |